Skip to content
Menu

Biofrontera Inc. BFRI

Full chart Compare
Set alert

Price alert · BFRI

All alert types
0.57 USD 0.00 (-0.82%)

As ofNov 20, 2026, 12:43 PM EST

0.5303 Day range 0.5882
0.5303 52-week range 1.66
YTD
-0.82%
1 year
-25.03%

5D -0.2846 (-31.29%)

0.60000.70000.80000.9000TueWedThuFriMon0.6251
Market cap
10.15M
Revenue (ttm)
35.24M
Profit margin
-38.34%
EPS (ttm)
-0.43
Shares out
7.75M
Forward P/E
-1.17
YTD return
-0.82%
1-year return
-25.03%
Volume
94.85K
Avg volume
432.96K
Open
0.5697
Previous close
0.57
Day's range
0.5303 – 0.5882
52-week range
0.5303 – 1.66
Beta
0.51
Price target
11.50 (+1934.3%)

Key statistics

50-day average
0.93324
200-day average
1.17
Enterprise value
959.18K
Price / sales
0.22
Price / book
0.32
Revenue growth
34.00%
Free cash flow
-17.96M
Total cash
4.39M
Total debt
1.44M
Return on equity
-149.41%
Short % of float
8.26%

Fundamental scorecard

6 of 25 checks passed on BFRI’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
BFRI Revenue — quarterly 9.07M
BFRI Net income — quarterly -6.42M
BFRI EPS — quarterly -0.42

Earnings

BFRI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.73-0.86-0.13-17.81%
Aug 14, 2024Jun 1, 2024-1.19———
Aug 14, 2024Jun 1, 2024-1.19-1.12+0.07+5.88%
May 15, 2024Mar 1, 2024-1.63———
May 15, 2024Mar 1, 2024-1.63-1.85-0.22-13.50%
Mar 15, 2024Dec 1, 20230.00-2.33——

Upgrades / downgrades

BFRI analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024BenchmarkreitBuyBuy
Aug 16, 2024BenchmarkreitBuyBuy
Aug 31, 2023BenchmarkreitBuyBuy

About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on BFRI — it syncs with the Stock Master app.

Insider holders

BFRI insider holders
InsiderRelationLatest transactionDateShares held
LUEBBERT HERMANNChief Executive OfficerConversion of Exercise of derivative securityMay 16, 202415,211
MONACO ERICA L.Chief Executive OfficerConversion of Exercise of derivative securityMay 17, 2023133,025

Institution ownership

BFRI institution ownership
Holder% heldSharesValueReported
AIGH Capital Management LLC6.47%501,434506.45KSep 29, 2024
Rosalind Advisors, Inc.6.39%495,490500.44KSep 29, 2024
Scotia Capital Inc.0.65%50,00050.50KSep 29, 2024
Geode Capital Management, LLC0.22%17,10217.27KSep 29, 2024
Blackrock Inc.0.06%4,6224.67KSep 29, 2024
UBS Group AG0.04%3,0993.13KSep 29, 2024

Fund ownership

BFRI fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.19%14,85815.01KOct 30, 2024
Vanguard Extended Market Index Fund0.11%8,6118.70KSep 29, 2024
Fidelity Series Total Market Index Fund0.05%3,7333.77KOct 30, 2024
Fidelity Total Market Index Fund0.01%422426Oct 30, 2024